Wedoany.com Report-Oct. 22, ACG (Mumbai, India; www.acg-world.com), a global leader in integrated solid-dosage solutions, announced a $200 million phased investment to launch its first empty-capsule manufacturing operations in the U.S. The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta, Georgia, with a second phase of $100 million planned to expand regional capacity and capabilities. The project is expected to create over 200 jobs, with operations targeted to begin in early 2027.

“ACG has served North America for over 25 years. This facility strengthens our ties with customers across the region—bringing us closer to them, enabling faster lead times, higher-quality service, and a more resilient, de-risked supply chain. Just as importantly, it lets us respond more quickly and co-develop new innovations through tighter R&D partnerships. It’s been a long time coming, and we’re glad to say it’s here,” said Karan Singh, Managing Director of ACG.

The Atlanta facility will produce both gelatin and vegetarian (HPMC) hard-shell capsules, designed and operated to meet the highest global standards for quality, safety, and regulatory compliance. This initiative aligns with ACG’s “Make it Better” commitment and complements the company’s U.S. ecosystem, which includes capsules, barrier packaging materials, processing and encapsulation machinery, visual inspection, and traceability solutions—supported by nationwide sales and service.

“Atlanta is the right location to execute at scale,” said Selwyn Noronha, CEO of ACG Capsules. “Georgia and the City of Atlanta offer a pro-business environment, a strong talent pipeline, world-class connectivity, and reliable infrastructure. Combined with ACG’s recent facility builds in Aurangabad (HPMC), Thailand (gelatin), and expansions in Brazil, Croatia, and India, we have the operating discipline to begin production quickly and deliver reliable supply for North American customers.”

ACG has maintained a presence in the United States for over 25 years, with its North American headquarters in Piscataway, New Jersey. The company manufactures liquid fill capsules in Chadds Ford, Pennsylvania, and operates several warehouses across the U.S., supported by nationwide sales and service teams.

This investment marks a strategic expansion of ACG’s footprint in North America, enhancing local manufacturing capabilities, shortening lead times, and improving supply chain resilience. By establishing dedicated facilities for gelatin and HPMC capsules, ACG aims to meet growing customer demand while maintaining high standards of safety, quality, and regulatory compliance.

The new operations will also strengthen ACG’s collaboration with U.S.-based partners and support co-development of innovative solutions, further advancing its mission to deliver reliable, high-quality products to the North American pharmaceutical and nutraceutical markets.

Overall, the phased investment underscores ACG’s commitment to the region, combining global expertise with local production to serve customers efficiently and sustainably.